Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · IEX Real-Time Price · USD
7.42
-0.02 (-0.27%)
At close: Mar 28, 2024, 4:00 PM
7.45
+0.03 (0.40%)
After-hours: Mar 28, 2024, 6:58 PM EDT
Editas Medicine Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 14.27, with a low estimate of 8.00 and a high estimate of 20. The average target predicts an increase of 92.32% from the current stock price of 7.42.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for EDIT stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Buy | 4 | 4 | 3 | 3 | 2 | 2 |
Hold | 8 | 8 | 6 | 6 | 6 | 6 |
Sell | 1 | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 17 | 17 | 14 | 14 | 12 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citigroup | Citigroup | Strong Buy Maintains $11 → $16 | Strong Buy | Maintains | $11 → $16 | +115.63% | Feb 29, 2024 |
Barclays | Barclays | Hold Maintains $10 → $11 | Hold | Maintains | $10 → $11 | +48.25% | Feb 29, 2024 |
JP Morgan | JP Morgan | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +21.29% | Feb 27, 2024 |
Truist Securities | Truist Securities | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +169.54% | Dec 12, 2023 |
Citigroup | Citigroup | Hold → Strong Buy Upgrades $11 | Hold → Strong Buy | Upgrades | $11 | +48.25% | Oct 24, 2023 |
Financial Forecast
Revenue This Year
29.98M
from 78.12M
Decreased by -61.62%
Revenue Next Year
27.48M
from 29.98M
Decreased by -8.35%
EPS This Year
-2.65
from -2.02
EPS Next Year
-2.78
from -2.65
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 67.2M | 56.5M | 254.1M | 1.0B | 1.2B |
Avg | 30.0M | 27.5M | 69.3M | 224.8M | 307.1M |
Low | n/a | n/a | 14.7M | 24.5M | 24.5M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -14.0% | 88.6% | 824.7% | 1,366.3% | 432.6% |
Avg | -61.6% | -8.3% | 152.1% | 224.4% | 36.6% |
Low | - | - | -46.5% | -64.6% | -89.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.93 | -1.82 | -1.49 | -0.96 | -0.47 |
Avg | -2.65 | -2.78 | -2.85 | -1.70 | -1.41 |
Low | -3.75 | -4.42 | -4.54 | -2.61 | -2.35 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.